Atorvastatin + Placebo

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Polycystic Ovary Syndrome

Conditions

Polycystic Ovary Syndrome

Trial Timeline

Sep 1, 2006 → Jan 1, 2011

NCT ID

NCT01072097

About Atorvastatin + Placebo

Atorvastatin + Placebo is a pre-clinical stage product being developed by Pfizer for Polycystic Ovary Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01072097. Target conditions include Polycystic Ovary Syndrome.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (9)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00756886	Pre-clinical	Completed	Sep 1, 2008	May 1, 2011	Arrhythmia
NCT00579098	Approved	Completed	Dec 1, 2007	Dec 1, 2011	Atrial Fibrillation
NCT00517257	Phase 3	UNKNOWN	Aug 1, 2007	Sep 1, 2009	Retinal Vein Occlusion
NCT00481364	Phase 3	Completed	Nov 1, 2006	Dec 1, 2008	Vascular Calcification
NCT01072097	Pre-clinical	Completed	Sep 1, 2006	Jan 1, 2011	Polycystic Ovary Syndrome
NCT00252967	Phase 3	Terminated	Oct 1, 2005	Oct 1, 2009	Atrial Fibrillation
NCT00233480	Approved	Completed	Aug 1, 2005	Feb 1, 2009	Heart Failure, Congestive
NCT00587379	Pre-clinical	Withdrawn	Jun 1, 2004	May 1, 2008	Endothelial Dysfunction
NCT00640549	Approved	Terminated	Mar 1, 2003	Oct 1, 2004	Hyperlipidemia

Competing Products

20 competing products in Polycystic Ovary Syndrome

See all competitors

Product	Company	Stage	Hype Score
Tildacerfont + Placebo	Spruce Biosciences	Phase 2	44
ABBV-CLS-628 + Placebo	AbbVie	Phase 2	52
Elagolix + Placebo	AbbVie	Phase 2	52
Metformin XR + Saxagliptin + Saxagliptin-Metformin XR	AstraZeneca	Phase 3	77
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ER	AstraZeneca	Phase 3	77
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B	AstraZeneca	Phase 1	33
AZD4901 (oral) + Placebo to match AZD4901	AstraZeneca	Phase 2	52
IVF Antagonist Protocol	Merck	Pre-clinical	23
tredaptive (nicotinic acid/ laropiprant) + placebo	Merck	Approved	85
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	77
Lisinopril + Telmisartan + Placebo	Merck	Phase 3	77
Cetrorelix acetate + Cetrorelix acetate + Recombinant Human Choriogonadotropin (r-hCG) + Recombinant human follicle stimulating hormone (r-hFSH)	Merck	Phase 3	77
Gonal-f® + Long GnRH agonist + GnRH antagonist	Merck	Pre-clinical	23
Placebo + Everolimus	Novartis	Approved	85
LIK066 + Placebo	Novartis	Phase 2	52
Octreotide + Placebo	Novartis	Phase 2/3	65
Everolimus + Calcineurin inhibitors maintenance	Novartis	Phase 3	77
Everolimus + Octreotide LAR	Novartis	Phase 2	52
Rapamune	Pfizer	Phase 1/2	40
Sirolimus	Pfizer	Phase 2/3	64

Other Products from Pfizer